Medicus Pharma Raises $90 Million for Asset Acquisitions

The drug developer will use the capital to advance its acquired portfolio through key clinical and regulatory milestones.

Updated on Oct. 15, 2026 in Corporate Finance

Medicus Pharma Raises $90 Million for Asset Acquisitions

Live Poll

Do you trust the long-term clinical development potential of small biotechnology companies?

Philadelphia-based drug developer Medicus Pharma has secured approximately $90 million in equity and debt financing over the past three years. The capital supports the firm's strategy of acquiring therapeutic assets and advancing them through clinical and regulatory milestones.

Why it matters

The infusion of $90 million underscores a business model focused on building a diversified portfolio by acquiring existing research foundations. For industry operators, this approach highlights the capital-intensive nature of moving assets like SkinJect through clinical stages toward regulatory authorization.

Medicus Pharma raised $90 million in total financing over a three-year period. The firm currently manages clinical assets including the SkinJect platform, for which FDA authorization was granted to initiate the SKNJCT-005 registrational study.

The players

Medicus Pharma

A Philadelphia-based pharmaceutical company that acquires therapeutic assets and advances them through clinical and regulatory milestones.

Antev

A biotech entity acquired by Medicus Pharma in August 2025 to bolster its drug-development portfolio.

The details

Medicus Pharma operates by acquiring therapeutic assets that possess existing research foundations to accelerate their path toward commercial viability. The company uses a linker-payload platform, such as its CD228V treatment, to deliver cancer-killing agents via targeted antibodies. It focuses spending on specific clinical and regulatory milestones while seeking future co-development or licensing agreements to offset development risks.

October 2023: Company initial listing on TSX Venture Exchange.
November 2024: Company moved to Nasdaq.
August 2025: Acquisition of Antev.

Market Landscape

Medicus Pharma aligns its operations with the standard drug-development cycle defined by the FDA registrational study pathway. This strategic focus mirrors industry efforts to validate novel targets like CD228, for which no approved treatments currently exist.

Operators in the biotech sector should track Medicus Pharma as it pursues licensing and co-development agreements for its expanded portfolio. Monitoring the progress of the SKNJCT-005 study will provide insight into the efficacy of the company's asset-acquisition model.

The takeaway

Medicus Pharma serves as a case study for firms aiming to scale through targeted acquisitions rather than solely internal R&D. Investors and partners should watch for future disclosures regarding strategic licensing deals as the company concentrates its $90 million in capital.